Dr Klaus Pors, a Medicinal Chemist based at the University’s Institute of Cancer Therapeutics, has been awarded £96,474 by Yorkshire Cancer Research to develop a medicine that is harmless to the body but will help to eradicate tumours by using the cancer cell to convert a drug from something inactive to a powerful cell-killing agent.
The research centres on a group of proteins found in all humans called Cytochromes P450 (CYPs), which are most commonly found in the liver. They form part of the body’s immune system and their job is to metabolise compounds in the liver and other filter organs, making these compounds more ‘polar’ and enabling harmful substances to be excreted out of the body via the urinary system.
Whilst there are 57 known types of CYPs, some are known to be more highly present in cancer cells compared to the surrounding normal tissue. Dr Pors aims to exploit them by essentially hijacking the CYPs in the tumour to produce an agent that is highly damaging to the cancer cell DNA whilst leaving normal healthy cells alone.
Dr Pors will be using the grant to employ a post-doctoral researcher to help develop these novel tumour-selective agents. He said: “A major obstacle in the treatment of cancer is the lack of selective killing of cancer cells. Clinicians currently use chemotherapeutic agents which generally damage normal tissues and lead to severe side-effects.
“It is envisaged that an agent would be administered to patients that produces no side-effects commonly associated with current therapies, but when reaching the tumour will be converted to an ultra-potent agent that causes the demise of the tumour.
“I’m delighted that Yorkshire Cancer Research has funded our work here, using money raised in the region for research in the region but more importantly, if our work is successful, patients all over the world could benefit from such highly targeted anti-cancer drugs that in principle will cause no harmful side-effects.”
Dr Pors and a team of researchers have spent the last 15 months analysing samples taken from cancer patients in Bradford and Leeds in order to get to this stage. If the lab-based work is successful, he hopes to move to Phase 1 Clinical Trials within five years.
Emma Banks | alfa
Flow of cerebrospinal fluid regulates neural stem cell division
22.05.2018 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt
Chemists at FAU successfully demonstrate imine hydrogenation with inexpensive main group metal
22.05.2018 | Friedrich-Alexander-Universität Erlangen-Nürnberg
There are videos on the internet that can make one marvel at technology. For example, a smartphone is casually bent around the arm or a thin-film display is rolled in all directions and with almost every diameter. From the user's point of view, this looks fantastic. From a professional point of view, however, the question arises: Is that already possible?
At Display Week 2018, scientists from the Fraunhofer Institute for Applied Polymer Research IAP will be demonstrating today’s technological possibilities and...
So-called quantum many-body scars allow quantum systems to stay out of equilibrium much longer, explaining experiment | Study published in Nature Physics
Recently, researchers from Harvard and MIT succeeded in trapping a record 53 atoms and individually controlling their quantum state, realizing what is called a...
The historic first detection of gravitational waves from colliding black holes far outside our galaxy opened a new window to understanding the universe. A...
A team led by Austrian experimental physicist Rainer Blatt has succeeded in characterizing the quantum entanglement of two spatially separated atoms by observing their light emission. This fundamental demonstration could lead to the development of highly sensitive optical gradiometers for the precise measurement of the gravitational field or the earth's magnetic field.
The age of quantum technology has long been heralded. Decades of research into the quantum world have led to the development of methods that make it possible...
Cardiovascular tissue engineering aims to treat heart disease with prostheses that grow and regenerate. Now, researchers from the University of Zurich, the Technical University Eindhoven and the Charité Berlin have successfully implanted regenerative heart valves, designed with the aid of computer simulations, into sheep for the first time.
Producing living tissue or organs based on human cells is one of the main research fields in regenerative medicine. Tissue engineering, which involves growing...
02.05.2018 | Event News
13.04.2018 | Event News
12.04.2018 | Event News
22.05.2018 | Life Sciences
22.05.2018 | Life Sciences
22.05.2018 | Trade Fair News